Kilitch Drugs (India) Limited (KILITCH) — Board Meeting | 13 August 2026

· NSE 🟡 Notable Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
📢 Key Event
Board approved unaudited Q1 June 2026 financial results
🔄 What Changed
Net profit declined to ₹505.24 lakhs standalone and ₹196.74 lakhs consolidated versus ₹1,399.90 lakhs and ₹1,488.28 lakhs in previous quarter
💡 Investor Takeaway
Profitability weakened significantly in the latest quarter compared to prior period

Kilitch Drugs approved unaudited standalone and consolidated financial results for Q1 June 2026, showing net profit of ₹505.24 lakhs standalone and ₹196.74 lakhs consolidated. The board reviewed results, auditor review confirmed no material misstatement, and disclosed key financial metrics including revenue and profit figures.

📄 View Original Announcement (PDF)

About Kilitch Drugs (India) Limited (KILITCH)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹599.24 Cr P/E: 13.7 ROE: 10.4% ROCE: 11.9%

View full KILITCH stock details →

📡 Get AI alerts when KILITCH files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track KILITCH — Free

📊 More KILITCH filings

See all KILITCH filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when KILITCH files new disclosures

Track KILITCH filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track KILITCH — Free

Free account · 2 AI queries/day